Table 5.
Worldwide studies on IgA nephropathy
| Author | Country | Year | Sample size | Mean age (years) | Hypertension (%) | Proteinuria (mean) | Gross hematuria (%) | Renal failure | M1 | E1 | S1 | T1 | T2 | C1/2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asian | ||||||||||||||
| Shi[38] | China | 2011 | 410 | 31 | NA | 1.7 g/day | 34 | 19% (CKD-III) | 56% | 57% | 75% | 14% | 8% | 60% |
| Katafuchi[19] | Japan | 1994 | 225 | 32 | 22 | 16% (>3 g/day) | 20 | 20% (CKD-III) | NA | NA | NA | NA | NA | NA |
| Katafuchi[39] | Japan | 2011 | 702 | 30 | NA | 0.9 (UPCR) | 20 | 30% | 12% | 42% | 79% | 18% | 12% | 63% |
| Kang[40] | Korea | 2012 | 197 | 32.4 | 24.4 | 2.07 g/day | 11.2 | NA | 74% | 11% | 56% | 26% | 8% | NA |
| Shima[29] | Japan | 2012 | 161 | 11.7 | NA | 0.7 g/day | 66 | NA | 64% | 58% | 8% | 1% | 0% | 52% |
| Zeng[22] | China | 2012 | 1026 | 34 | 33 | 1.3 g/day | 34 | 59% | 43% | 11% | 83% | 24% | 3% | 48% |
| Lee[24] | Korea | 2012 | 69 | 34 | NA | 1.2 g/day | 27 | 64% | 61% | 32% | 80% | 25% | 12% | NA |
| Le[25] | China | 2012 | 218 | 14 | 6.5 | 1.5% | 57 | NA | 45% | 23% | 62% | 7% | 1% | 56% |
| Kataoka[41] | Japan | 2011 | 43 | NA | NA | NA | NA | NA | 81% | 53% | 81% | NA | NA | 53% |
| Moriyama[42] | Japan | 2012 | 42 | 34.2 | NA | NA | NA | NA | 60% | 43% | 83% | 40% | 26% | NA |
| Yoon[43] | Korea | 2012 | 377 | NA | NA | NA | NA | NA | 20% | 23% | 61% | 11% | 0% | NA |
| Zhang[28] | China | 2018 | 1152 | 35.4 | 33.1 | 1.42 g/day | NA | NA | 43% | 42% | 77% | 33% | 0% | 36% |
| Current study European | India | 2020 | 560 | 32 | 69.8 | 3.61 g/day | 4.6 | 68% | 67% | 24% | 47% | 28% | 5% | 20% |
| Edstrom[44] | Sweden | 2011 | 99 | 9.4 | NA | NA | NA | NA | 31% | 10% | 23% | 12% | 5% | 18% |
| Almartine[23] | France | 2011 | 183 | NA | NA | NA | NA | NA | 21% | 14% | 54% | 20% | 10% | 5% |
| Coppo[26] | Europe | 2014 | 1147 | 36% | 65 | 1.3 g/day | NA | 37% (CKD-III or more) | 28% | 11% | 70% | 17% | 45 | 11% |
| Stefan[27] | Romania | 2016 | 121 | 40.1 | 58 | 2.0 g/day | NA | NA | 72% | 23% | 79% | 71% | NA | 31% |
| Elkarou[45] | France | 2011 | 128 | NA | NA | NA | NA | NA | 34% | 25% | 69% | 26% | 23% | 24% |
| Gutirrez[46] | Spain | 2012 | 141 | 23.7 | NA | 0.2 g/day | 100 (MSH) | NA | 33% | 9% | 16% | 5% | 0% | NA |
| North America | ||||||||||||||
| Yau[47] | USA | 2011 | 54% | 41 | 48 | 72% (>1 g/day) | 24 | 31.1% | 72% | 20% | 81% | 13% | 22% | 19% |
| Multinational | ||||||||||||||
| Oxford[18] | Multi | 2009 | 265 | 30 | 31 | 1.7 g/day | NA | 64% (CKD-III or more) | 80.6% | 42% | NA | NA | NA | 45% |
| Barbour[48] | Multi | 2015 | 901 | 38.1 | NA | 1.5 g/day | NA | NA | 43% | 18% | 75% | 18% | 4% | 17% |
C=crescent, E=endocapillary hypercellularity, IgAN=IgA nephropathy, M=mesangial hypercellularity, S=segmental sclerosis, T=tubular atrophy, uPCR, urinary protein creatinine ratio